About
Dr. Collins has served as our Executive Vice President since August 2019 and Chief Medical Officer since March 2017. She also served as Senior Vice President from March 2017 to August 2019 and Vice President of Clinical Development from June 2016 to March 2017. From June 2013 to June 2016, Dr. Collins held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Program and Clinical Lead for Gilead’s GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs. From November 2009 to May 2013, Dr. Collins held positions of increasing responsibility at Amgen Inc., most recently as Global Lead, Oncology Biosimiliars. Prior to joining Amgen, Dr. Collins practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group (RRMG) and served as President of RRMG from 2006 to 2009. In 2005, Dr. Collins co-founded the non-profit North Bay Cancer Alliance (NBCA), whose mission is to increase local access to education and cancer care in counti
Position in the VCSift Database
- • 48 investors hold the Co-Founder and Co-CEO role in VCSift. Helen Collins is one of them.
- • 10 investors are based in Leicester, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Leicester, UK
Contact Information
Find more investors like Helen
Search Investors